!!Timothy Cox - Curriculum Vitae
\\
__University Education and Professional Qualifications:__
\\
*1966 - 1971 The London Hospital Medical College, London University, MB, BS (Price Entrance Scholar in Science; Anderson Prize Medicine & Pathology)\\
*1973  Membership Royal College of Physicians UK\\
*1976 - 1978 Chelsea College, (Kings College), London University, MSc General Biochemistry\\
*1975 - 1979 Royal Postgraduate Medical School, Imperial College, London, MD by Thesis - Cell Biology\\
*1984  Fellow Royal College of Physicians London\\
*1991  University of Cambridge MD (higher Doctorate by publication), Medical Science\\
*1998  Fellowship, Academy of Medical Sciences, UK
\\
An Internist and Metabolic Physician, Professor Tim Cox’ laboratory studies molecular pathogenesis of inborn errors and conducts therapeutic research in lysosomal diseases alongside a National Specialist Service in the NHS, which he initiated. He has supervised 20 PhD students.\\
\\
His current focus is sphingolipid disorders: studies of in vivo molecular targeting and efficacy of therapeutic enzymes and biomarker discovery which have led to pivotal clinical trials of biosynthetic inhibitors for sphingolipidoses and a developmental gene therapy for GM2 gangliosidosis. N-butyldeoxynojirimycin (miglustat) was the first substrate inhibitor approved for Gaucher and Niemann-Pick type C diseases: eliglustat, is a globally approved first-line oral therapy for non-neuronopathic Gaucher disease.\\
\\
He is also a principal investigator in clinical trials of the brain-penetrant congener -venglustat- in neuronopathic Gaucher disease and attenuated Tay-Sachs and Sandhoff diseases.\\
\\
His career and experience as Founding Director of the Cambridge MD/PhD program (first in UK) involved clinical medicine, research and teaching.\\
\\
An invited participant in Gordon Research Conferences on Lysosomal Diseases in 2011 (inaugural keynote), 2015 and 2017 (Keynotes at GRC and GRS) elected Vice-Chair and Chair 2017-21; with JMFG Aerts, Tim Cox founded the European Study Group in Gaucher Disease.\\
\\
Patron or Honorary Consultant Advisor to five disease-related patient charities in the field of lysosomal and metabolic diseases, he serves committees for international, biopharmaceutical and charity-sponsored scientific meetings. Among his several honorary functions, he was Président of the Translational Research Committee, Agence Nationale de le Rercherche, France (2013-16) and is the Vice-Chair of the Croucher Foundation, Hong Kong (2013-).\\ \\